The aim of this project is to define clinically useful molecular-oriented early detection of minimal disease in ovarian cancer that can identify patients not responding to the standard therapy at the time of surgery. This will eventually lead to alternative therapy modalities, which can bring benefits to this group of patients. Signatures that signal the presence of minimal disease will be systematically investigated at various molecular levels (DNA, RNA, and protein) and in a broad spectrum of biological materials (tumor tissue, circulating and disseminated tumor cells, sera, white blood cells, ascites) from ovarian cancer patients. Profiling of chromosomal loss or gain, gene methylation and mutations, mRNA expression and protein will be analyzed. Specific signatures that predicts patients´ outcome or indicate minimal residual disease, eventually suitable for early primary diagnosis, will be extracted.


Duration 01/01/2006 - 30/06/2010
Funding EU
Program 6. Rahmenprogramm

Department for Biomedical Research

Center for Biomedical Technology

Principle investigator for the project (University for Continuing Education Krems) Univ.-Prof. Dr. Viktoria Weber


Eifler, R.; Lind, J.; Falkenhagen, D.; Weber, V.; Fischer, M.B.; Zeillinger, R. (2011). Enrichment of circulating tumor cells from a large blood volume using leukapheresis and elutriation: a proof of concept. Cytometry B Clin Cytom 80(2): 100-111

Eifler, R. (2010). Proof of concept to enrich and isolate circulating tumor cells using leukapheresis, elutriation and flow cytometry. Doctor Thesis


Extracorporeal Separation of Tumor Cells

8th International Life Science Meeting, 28.-29.4.2011, Krems, Austria, 28/04/2011

Back to top